NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts have given NRx Pharmaceuticals a consensus rating of Moderate Buy from six brokers (4 buys, 1 hold, 1 sell) with an average 1‑year price target of $38.00.
• Several firms recently raised targets, including HC Wainwright to $45 and Ascendiant Capital Markets to $48, while Weiss Ratings maintained a sell stance.
• NRx reported a quarterly EPS of $0.19 versus estimates of (‑$0.09), but revenue was just $0.98M versus $7.53M expected, and sell‑side forecasts still project about (‑1.75) EPS for the year.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $38.00.

Several analysts recently commented on the company. HC Wainwright raised their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, March 3rd. D. Boral Capital reaffirmed a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Ascendiant Capital Markets reaffirmed a "buy" rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Finally, Zacks Research raised NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Anson Funds Management LP grew its holdings in NRx Pharmaceuticals by 26.2% during the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company's stock worth $6,683,000 after acquiring an additional 420,129 shares during the period. Geode Capital Management LLC grew its holdings in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after acquiring an additional 37,598 shares during the period. Vanguard Group Inc. grew its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company's stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $994,000. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $2.22 on Friday. The stock's 50-day simple moving average is $1.95 and its 200-day simple moving average is $2.37. The firm has a market capitalization of $73.42 million, a PE ratio of -1.60 and a beta of 1.83. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.28. The firm had revenue of $0.98 million during the quarter, compared to analyst estimates of $7.53 million. Sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.